Pharma News

Kodak Pharmaceutical deal under scrutiny

Home/Pharma News | Posted 11/09/2020

In late July 2020, US President Donald Trump announced that the Federal Government would be loaning Eastman Kodak Co US$765 million to develop generic drugs. This is the first loan to be granted under the US Defense Production Act that was passed in response to the global COVID-19 pandemic. Now, amid allegations of insider trading, the House of Representatives will review the Kodak Pharmaceutical deal and there will be a Securities and Exchange Commission (SEC) investigation.

Bio-Thera partners with Pharmapark to market golimumab biosimilar in Russia and other CIS countries

Home/Pharma News | Posted 04/09/2020

China-based biopharmaceutical company Bio-Thera Solutions (Bio-Thera) announced on 18 July 2020 that it has signed a licensing agreement for its proposed golimumab biosimilar BAT2506 with Russia-based Pharmapark.

Teva changes course in Japan and the US

Home/Pharma News | Posted 28/08/2020

Israeli drugs manufacturer Teva has made strategic decisions in the US and Japan. The company plans to strip back its Japanese venture with Takeda, selling off parts of the portfolio by early 2021. However, in the US, Teva will be entering a strategic partnership with Alvotech for the commercialization of five biosimilar candidates.

Perrigo sells its UK generic drug business

Home/Pharma News | Posted 24/07/2020

Perrigo Co Plc (Perrigo) has sold its generic prescription drug business to a private equity firm in a deal worth US$195 million.

COVID-19 drug trials underway

Home/Pharma News | Posted 10/07/2020

There are over 200 trials for COVID-19 currently in progress. These include trials of monoclonal antibodies, including from the South Korean firm Celltrion, as well as vaccines, notably from the Chinese firm CanSino Biologics.

Aurobindo/Sandoz deal falls through, biosimilars business transferred to subsidiary

Home/Pharma News | Posted 19/06/2020

It has been announced that Aurobindo Pharma’s planned deal to take over the US generic oral solids and dermatology businesses of Sandoz has fallen through. More recently, the company has transferred its biosimilars business to its wholly owned subsidiary CuraTeQ Biologics.

Fresenius Kabi signs marketing agreement for adalimumab biosimilar

Home/Pharma News | Posted 05/06/2020

German pharmaceutical company Fresenius Kabi has signed an agreement with methotrexate supplier Medac for the sale of its adalimumab biosimilar Idacio. The agreement is likely to boost sales of Idacio.

Success for Celltrion in Japan and Samsung Bioepis in Europe

Home/Pharma News | Posted 29/05/2020

South Korean biosimilar manufacturer Celltrion’s trastuzumab biosimilar has gained a 40% market share in Japan. Meanwhile, Samsung Bioepis, which is also headquartered in South Korea, announced European sales in excess of US$200 million in the first quarter of 2020.

Canadian firm Bausch + Lomb signs agreement on Lucentis biosimilar

Home/Pharma News | Posted 22/05/2020

Canadian eye health specialists Bausch + Lomb have signed an exclusive licensing agreement with Stada and its development partner Xbrane to develop and commercialize a Lucentis biosimilar in Canada and the US.

Mycenax sells tocilizumab biosimilar to Richter

Home/Pharma News | Posted 08/05/2020

Taiwanese biosimilars developer Mycenax announced on 28 April 2020 that it had made a deal with Hungary-based Gedeon Richter (Richter) regarding its tocilizumab biosimilar.